Assessing strategies to target screening for advanced liver fibrosis among overweight and obese patients

Abstract

Aim: The optimal screening strategy for advanced liver fibrosis in overweight and obese patients is unknown. The aim of this study is to compare the performance of different strategies to select patients at high risk of advanced liver fibrosis for screening using non-invasive tools.

Methods: All patients underwent: liver ¹H-MRS and percutaneous liver biopsy (in those with nonalcoholic fatty liver disease [NAFLD]). Unique selection strategies were compared to determine the best screening algorithm: (A) A "metabolic approach": selecting patients based on HOMA-IR ≥ 3; (B) A "diabetes approach": selecting only patients with type 2 diabetes; (C) An "imaging approach": selecting patients with hepatic steatosis based on ¹H-MRS; (D) A "liver biochemistry approach": selecting patients with elevated ALT (i.e., ≥ 30 IU/L for males and ≥ 19 IU/L for females); and (E) Universal screening of overweight and obese patients. FIB-4 index, NAFLD fibrosis score, and APRI were applied as screening strategies.

Results: A total of 275 patients were included in the study. Patients with advanced fibrosis (n = 29) were matched for age, gender, ethnicity, and BMI. Selecting patients by ALT elevation provided the most effective strategy, limiting the false positive rate while maintaining the sensitivity compared to universal screening. Selecting patients by any other strategy did not contribute to increasing the sensitivity of the approach and resulted in more false positive results.

Conclusion: Universal screening of overweight/obese patients for advanced fibrosis with non-invasive tools is unwarranted, as selection strategies based on elevated ALT levels lead to the same sensitivity with a lower false positive rate (i.e., fewer patients that would require a liver biopsy or referral to hepatology).

Keywords

Nonalcoholic fatty liver disease / NAFLD / diagnosis / NASH / non-invasive

References

[1] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[2] Younossi Z,Marietti M.Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.Nat Rev Gastroenterol Hepatol2018;15:11-20

[3] Younossi ZM,de Avila L.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol2019;71:793-801

[4] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.Hepatology2018;67:328-57

[5] Bril F,Caulfield MP.Performance of plasma biomarkers and diagnostic panels for nonalcoholic steatohepatitis and advanced fibrosis in patients with type 2 diabetes.Diabetes Care2020;43:290-7

[6] Mózes FE,Selvaraj EA.LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.Gut2022;71:1006-19 PMCID:PMC8995830

[7] European Association for the Study of the Liver (EASL)., European Association for the Study of Diabetes (EASD)., European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.J Hepatol2016;64:1388-402

[8] Kanwal F,Adams LA.Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.Gastroenterology2021;161:1657-69 PMCID:PMC8819923

[9] Bril F,Kalavalapalli S.Intact fasting insulin identifies nonalcoholic fatty liver disease in patients without diabetes.J Clin Endocrinol Metab2021;106:e4360-71

[10] Bril F,Liu IC.Clinical and histologic characterization of nonalcoholic steatohepatitis in African American patients.Diabetes Care2018;41:187-92

[11] Cusi K,Bril F.Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.Ann Intern Med2016;165:305-15

[12] Bril F,Lomonaco R.Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.Liver Int2015;35:2139-46

[13] Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.Diabetologia2016;59:1121-40

[14] Sanyal AJ,Kleiner DE.Endpoints and clinical trial design for nonalcoholic steatohepatitis.Hepatology2011;54:344-53 PMCID:PMC4014460

[15] Kleiner DE,Van Natta M.Nonalcoholic Steatohepatitis Clinical Research NetworkDesign and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology2005;41:1313-21

[16] Godinez-Leiva E.Nonalcoholic Fatty Liver Disease (NAFLD) for primary care providers: beyond the liver.Curr Hypertens Rev2021;17:94-111

[17] Portillo-Sanchez P,Maximos M.High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels.J Clin Endocrinol Metab2015;100:2231-8 PMCID:PMC6287506

[18] Diabetes Association. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2022.Diabetes Care2022;45:S46-59

[19] Lomonaco R,Bril F.Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening.Diabetes Care2021;44:399-406 PMCID:PMC7818321

[20] Dulai PS,Patel J.Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.Hepatology2017;65:1557-65 PMCID:PMC5397356